Roche Says Data From Lung Cancer Trial Was Inadvertently Disclosed

By Adria Calatayud

Roche Holding said data from a late-stage clinical trial evaluating a lung-cancer treatment has been inadvertently disclosed, and that the study will continue until a final analysis for overall survival has been completed.

The Swiss pharmaceutical giant said Wednesday that there was an inadvertent disclosure of the second interim analysis of the phase 3 trial when interim results for the overall survival rate--a primary goal of the trial--weren't mature.

The study is continuing and remains blinded to patients and investigators, the company said.

The trial evaluates immunotherapy tiragolumab in combination with antibody Tecentriq against Tecentriq alone as an initial treatment for people with a particular case of advanced or metastatic non-small cell lung cancer, Roche said.

The interim results showed an estimated median overall survival of 22.9 months for patients who received the combination, against 16.7 months for those who were in the monotherapy arm, the company said. The combination of tiragolumab plus Tecentriq was well tolerated, it said.

Write to Adria Calatayud at [e-mail]

(END) Dow Jones Newswires

August 23, 2023 02:41 ET (06:41 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.